echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Cell Death Dis: miR-526b-3p inhibits cisplatin resistance and metastasis of lung cancer

    Cell Death Dis: miR-526b-3p inhibits cisplatin resistance and metastasis of lung cancer

    • Last Update: 2021-08-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Platinum therapy is one of the most common chemotherapy strategies for a variety of solid cancers, including lung cancer
    .


    The treatment strategy of cisplatin combined with radiotherapy has been used in the treatment of advanced lung cancer


    Platinum therapy is one of the most common chemotherapy strategies for a variety of solid cancers, including lung cancer


    Side effects and drug resistance are two major challenges that limit the application of cisplatin and the response to treatment
    .


    Increasing evidence shows that the levels of STAT3, MEK1, and AKT are often dysregulated in cisplatin-resistant cancers


    miRNA is an endogenous non-coding RNA that contains less than 25 nucleotides
    .


    miRNA can bind to the 3'-UTR (3'-untranslated region) of the target mRNA, and ultimately lead to the degradation and inhibition of the mRNA


    miRNA is an endogenous non-coding RNA that contains less than 25 nucleotides



    The expression of miR-526b-3p decreases in cisplatin-resistant lung cancer

    The expression of miR-526b-3p decreases in cisplatin-resistant lung cancer

    More and more studies have shown that PD-L1 plays a vital role in regulating the cisplatin resistance of lung cancer
    .


    However, the underlying molecular mechanism remains unclear


    PD-L1 plays a vital role in regulating the cisplatin resistance of lung cancer



    Overexpression of STAT3 can reverse the inhibitory effect of miR-526b-3p in cancer metastasis

    Overexpression of STAT3 can reverse the inhibitory effect of miR-526b-3p in cancer metastasis

    All in all, the results of this study reveal a new mechanism of PD-L1 mediated lung cancer resistance to cisplatin
    .


    In addition, miR-526b-3p may provide new clues for improving the anti-tumor effect of the combination of immunotherapy and chemotherapy


    The results of this study reveal a new mechanism of PD-L1-mediated lung cancer resistance to cisplatin



    Chen, Kb.
    , Yang, W.
    , Xuan, Y.
    et al.
    miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.
    Cell Death Dis 12, 748 (28 July 2021) .

    miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1.

     

    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.